Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.
Status:
Completed
Trial end date:
2021-03-24
Target enrollment:
Participant gender:
Summary
Phase II study designed to investigate antitumor activity in terms of objective response rate
(ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will
be administered orally until disease progression.